Clinical Trial: Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine (RZV) in Frail Patients: Multicentric Prospective Study

U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07321808) titled 'Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine (RZV) in Frail Patients: Multicentric Prospective Study' on Dec. 22, 2025.

Brief Summary: Herpes zoster (HZ) is a serious health problem whose incidence and severity increase with the decline of cell-mediated immunity (CMI) because of age and immunocompromised (IC) status [4]. Subclinical reactivation are described and may boost the adaptive specific immunity. T cells play a major role in preventing reactivation of Varicella Zoster virus (VZV), with a contribution of both CD4 and CD8 T cells. Accordingly, the suppression of VZV-specific T cells preceded the occu...